Company News: Page (1) of 1 - 06/11/14

Caliber Imaging & Diagnostics' VivaScope(R) System Featured on Boston's ABC-TV Affiliate and Ivanhoe Broadcast News

June 11, 2014 --

BOSTON and ROCHESTER, N.Y., June 11, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., was featured in two recent media reports.



On May 18, Caliber I.D. was the focus of a news segment on the ABC-TV affiliate in Boston (WCVB-TV) and an accompanying article. The segment, titled "Optical biopsy diagnoses skin cancer without surgery: New biopsy method promises no cutting, no scars," focuses on the advantages of the Company's FDA-cleared VivaScope system to perform the VivaScan™ procedure, for diagnosing skin cancer without an invasive biopsy in the majority of cases. During the segment, Dr. Daniel Mark Siegel, clinical professor of dermatology at The State University of New York Health Science Center and a member of Caliber I.D.'s Board of Directors, says, "This is a technology whose time has come… We can look at one surface of the skin and then we can work our way down through deeper layers just like doing a CAT scan of the skin."



To view the segment and read the article, please visit the following link: http://www.wcvb.com/health/optical-biopsy-diagnoses-skin-cancer-without-surgery/25695518#!OKWyt


On June 4, Caliber I.D.'s VivaScope system was the subject of a video segment, online article and Q&A distributed by Ivanhoe Broadcast News, the country's largest television news-gathering organization covering medical breakthrough stories, discoveries in science and health stories. Ivanhoe has a client base of more than 250 television network affiliates in the United States, reaching 80 million households every day. To date, the segment has been broadcast by WJRT-TV, the ABC affiliate in Flint, MI; WJXT-TV, an independent station in Jacksonville, FL; and ScienceDaily, a consumer website with an average of six million visitors per month.




To read the Ivanhoe article, titled "More VivaScope: Fewer Biopsies," please visit the following link: http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=33340



To read a research summary of the Ivanhoe article, please visit the following link: http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=33341&channelid=CHAN-10001



To read a Q&A Ivanhoe conducted about VivaScope with Babar K. Rao, MD, of the Department of Dermatology at Rutgers' Robert Wood Johnson Medical School, please visit the following link: http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=33342&channelid=CHAN-10001



To view the Ivanhoe video segment in its entirety, please visit the following link: http://www.sciencedaily.com/videos/abd1f88433aca70691530d531c659929.htm



The videos at the links above are provided for informational purposes only. Caliber Imaging & Diagnostics is not responsible for the content of the linked videos.



About Caliber Imaging & Diagnostics



Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.



VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.



VivaScan™ is a trademark of Caliber Imaging and Diagnostics



Safe Harbor



This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.


CONTACT: Caliber Imaging & Diagnostics
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
or
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com

Page: 1
Related Keywords: MEDICALBroadcast, Prosumer/Consumer, Business, Broadcast Technology, Broadcast, USA, Inc., Surgery, healthcare, medical technologists, Cancer, Technology, Surgery, Science, Television, Medical Technology, Medical, Cancer, Business, Science, Other,

Source:2014 GlobeNewswire, Inc. . All Rights Reserved
---

@ Copyright, 2014 Digital Media Online, All Rights Reserved

Webmaster
Digital Media Online, Inc.